Aroa Biosurgery Ltd · ASX:ARX
Aroa Biosurgery — Investor Presentation (October 2026)
26 slides from Aroa Biosurgery's investor presentation, Oct 12, 2026
Slide 1: Aroa Biosurgery (ARX) – Symphony Randomised Controlled Trial
rsonal use only Aroa Biosurgery (ARX) – Symphony Randomised Controlled Trial UNLOCKING REGENERATIVE HEALING FOR EVERYBODY 1
Slide 2: Important Notice and Disclaimer
Important Notice and Disclaimer This presentation (12 Oct 2026) has been prepared by Aroa Biosurgery Limited, New Zealand company number 1980577, ARBN 638 867 473. This presentation: rsonal use only • Is for information purposes only and does not contain all information relevant or necessary for an
Slide 3: Contents
CONTENTS rsonal use only 01 Introduction 02 Overview 03 Symphony RCT 04 What this means 05 Q&A 3
Slide 4: Introduction: Substantial opportunity >US$1B
Introduction rsonal use only Substantial opportunity >$US1B Significant market disruption. Reimbursement reset to a flat fee. Physicians now require proven products at a reasonable price. | Unlocking regenerative healing for everybody. 4
Slide 5: Chief Scientific Officer Barnaby C. H. May, Ph.D.
rsonal use only CHIEF SCIENTIFIC OFFICER Barnaby C. H. May, Ph.D. 5 | Unlocking regenerative healing for everybody.
Slide 6: Symphony Proliferative Bioscaffold
Symphony Proliferative Bioscaffold For advanced wound closure rsonal use only What is Symphony? Symphony is an advanced composite cellular and tissue product (CTP), comprising layers of AROA ECM, with a layer of | Unlocking regenerative healing for everybody. hyaluronic acid 6
Slide 7: Symphony Proliferative Bioscaffold: Containing HMWHA
Symphony Proliferative Bioscaffold Containing high molecular weight hyaluronic acid (HMWHA) rsonal use only Why add a layer of hyaluronic acid (HA)? • HA is a naturally occurring component of tissue ECM and plays an important role in accelerating soft tissue repair, including angiogenesis, cell prol
Slide 8: Addition of HMWHA increases keratinocyte migration
Symphony Proliferative Bioscaffold Addition of HMWHA increases keratinocyte migration • Wound closure occurs via migration of keratinocytes rsonal use only The addition of HMWHA to OFM increases keratinocyte migration* ✱✱✱✱ ✱✱✱✱ 150 % Keratinocyte Migration ns ✱✱✱✱ 100 | Unlocking regenerative heali
Slide 9: Study design in the context of coverage
Armstrong et al | RCT Study design in the context of coverage rsonal use only Typical LCD / payer coverage criterion How the Symphony RCT satisfies Chronic DFU present ≥ 4 weeks despite RCT enrolled ulcers present ≥ 4 weeks that had failed to respond to conservative conservative care management, fol
Slide 10: Senior Medical Science Liaison Brandon Bosque, DPM
rsonal use only SENIOR MEDICAL SCIENCE LIAISON Brandon Bosque, DPM 10 | Unlocking regenerative healing for everybody.
Slide 11: Composite Ovine Forestomach Matrix and HA for Wagner 1 and 2 DFUs: RCT
rsonal use only A Composite Ovine Forestomach Matrix and Hyaluronic Acid CAMP for the Treatment of Wagner Grade 1 and 2 Diabetic Foot Ulcers: A Randomized Controlled Trial | Unlocking regenerative healing for everybody. David G. Armstrong, Dennis P. Orgill, Robert D. Galiano, John C. Lantis, Alexand
Slide 12: Study snapshot
Armstrong et al | RCT Study snapshot rsonal use only Design Population Control Intervention Endpoints Proportion of Prospective, patients healed multicenter, Adults with chronic Symphony + SOC Standard of care after 12-weeks parallel-group Wagner Grade 1 (SOC) alone Randomized and 2 DFUs (OFM-HA + S
Slide 13: Study protocol
Armstrong et al | RCT Study protocol rsonal use only 2 w run-in period Weekly treatment visits till closure, or TV13 2 w following closure Screening and TV1, either Healing enrollment TV13 Symphony or SOC confirmation visit | Unlocking regenerative healing for everybody. 13
Slide 14: Enrollment and populations
Armstrong et al | RCT Enrollment and populations Modified intent- Per protocol (PP) rsonal use only to-treat (mITT) 68 57 OFM-HA+SOC OFM-HA+SOC 197 143 | Unlocking regenerative healing for everybody. SCREENED FOR RANDOMIZED ELIGIBILITY 72 52 SOC ALONE SOC ALONE 14
Slide 15: Subject-related variables
Armstrong et al | RCT Subject-related variables Variable OFM-HA + SOC SOC p rsonal use only Age (years)(SD) 59.5 (9.87) 61.0 (10.25) 0.40 BMI (SD) 29.9 (6.04) 31.0 (7.21) 0.49 Diabetes duration (years)(SD) 18.4 (10.45) 15.2 (10.21) 0.048 Prior DFU count (SD) 2.6 (3.22) 3.1 (2.98) 0.19 Concurrent DFU
Slide 16: Ulcer-related variables
Armstrong et al | RCT Ulcer-related variables rsonal use only Variable OFM-HA plus SOC SOC P Wound area (cm2)(SD) 3.0 (3.41) 4.2 (4.53) 0.078 Wound age (weeks)(SD) 17.7 (11.32) 17.6 (12.61) 0.66 Plantar (%) 48 (71) 47 (65) 0.59 Medial (%) 41 (60) 40 (56) 0.47 Forefoot (%) 36 (53) 32 (45) 0.53 Depth
Slide 17: Primary endpoint: Incidence of closure at 12-weeks
Armstrong et al | RCT Primary endpoint: Incidence of closure at 12-weeks mITT: p=0.008 rsonal use only 46% vs 24% OFM-HA+SOC SOC alone 31/68 17/72 PP: p=0.033 | Unlocking regenerative healing for everybody. 54% vs 33% OFM-HA+SOC SOC alone 31/57 17/52 17
Slide 18: Secondary endpoint: Time to closure
Armstrong et al | RCT Secondary endpoint: Time to closure mITT: p=0.023 rsonal use only 67.4 vs 75.2 OFM-HA+SOC SOC alone (days) (days) PP: p=0.041 | Unlocking regenerative healing for everybody. 65.4 vs 73.2 OFM-HA+SOC SOC alone (days) (days) Shown Kaplan Meir survival curve for mITT population 18
Slide 19: Secondary endpoint: Adverse events
Armstrong et al | RCT Secondary endpoint: Adverse events OFM-HA+SOC (mITT) rsonal use only 50% 13% 1 1 AE RATE INDEX ULCER OSTEO/ MINOR INFECTIONS GANGRERE AMPUTATION SOC alone (mITT) | Unlocking regenerative healing for everybody. 51% 17% 7 3 AE RATE INDEX ULCER OSTEO/ MINOR INFECTIONS GANGRERE AMP
Slide 20: Next slide contains wound imagery
rsonal use only imagery Next slide contains wound 20 | Unlocking regenerative healing for everybody.
Slide 21: Case Example: Right Plantar Midfoot DFU
Case Example: Right Plantar Midfoot DFU A. B. 58-Year-old, male - Wagner 2 DFU Right rsonal use only Plantar Foot • A. Day 0: 2.6 x 1.2 x 0.1 cm • B. Week 1, 84% area reduction • C. Week 3, 90% area reduction C. • D. Week 4, 100% epithelialized D. | Unlocking regenerative healing for everybody. No c
Slide 22: Summary
Armstrong et al | RCT Summary rsonal use only • OFM-HA+SOC was effective in a mixed Wagner 1 and 2 population • Significantly increased incidence of wound closure – 57% more DFUs closed with OFM-HA+SOC vs SOC alone • Significantly reduced mean time to wound closure – closure reduced by 7.8 days (mea
Slide 23: Founder and Chief Executive Officer Brian Ward, BVSc MBA
rsonal use only FOUNDER AND CHIEF EXECUTIVE OFFICER Brian Ward, BVSc MBA
Slide 24: What this means
What this means rsonal use only Confidence Demonstrates efficacy Audit Defensibility from RCT study design, which is important product choice is clinical CRO & authors for adoption and not financial Supports Payor Supports Value Analysis Coverage Committee Processes Unlocks Sales CMS/MACs & private
Slide 25: Questions & Answers
rsonal use only AROA BIOSURGERY Questions & Answers 25
Slide 26: Thank you for attending
Thank you rsonal use only for attending investor@aroa.com Visit www.aroa.com www.linkedin.com/company /aroa-biosurgery-limited/ 64 Richard Pearse Drive, Auckland 2022, New Zealand PO Box 107111, Auckland Airport, Auckland 2150, New Zealand 26
Aroa Biosurgery — Investor Presentation (October 2026) on 6ix